$17.25 Million Boost for VitriVax Signals a Shift in How Vaccines Could Reach the Unreached
When biotech firm VitriVax raised $17.25 million in a Series B funding round, co-led by Adjuvant Capital and RA Capital Management, LP, it revealed more than just money changing hands—it spotlighted a broader fracture point in global immunisation strategy. Based in Boulder, Colorado, VitriVax is tackling two fundamental hurdles in vaccine delivery: the cold-chain barrier and the logistical burden…
